Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

Inclusion Criteria:

All patients must sign an informed consent indicating that they are aware of the investigational nature of this study; patients must also have signed an authorization for the release of their protected health information
Patients must have histologically confirmed adenocarcinoma of the prostate recurring after local therapy (radical prostatectomy and/or radiation therapy) as evidenced by rising serum PSA
Prostate-Specific Antigen (PSA) Doubling Time (PSADT) =< 12 months after local therapy (prostatectomy and/or definitive radiation) as determined by linear regression of all available PSA values within 6 months of initiation of androgen ablation (for patients who underwent prostatectomy, at least one PSA measurement of >= 1.0 ng/mL; for patients who underwent radiation, at least one PSA measurement of >= 3.0 ng/mL and >= 150% postradiation nadir)
No evidence of metastasis as determined by bone scan or computed tomography (CT) scan
Initiation of Androgen Ablation of less than 8 weeks' duration prior to study entry is permitted
Leukocytes ≥ 3,000/mcl
Absolute neutrophil count ≥ 1,000/mcl

Hemoglobin ≥ 8.0g/dl

Eligibility level for hemoglobin may be reached by transfusion
Platelet count >= 100,000/μL
Total bilirubin ≤1.5 X laboratory ULN
AST and/or ALT ≤ 3 X laboratory ULN
Creatinine ≤ 1.5 X laboratory ULN OR calculated creatinine clearance ≥ 60 ml/min/1.73 m^2 for patients w/creatinine levels above the laboratory ULN
Serum cholesterol level < 350 mg/dl
Triglyceride level < 300mg/dl
ECOG performance status 0, 1 or 2
The effects of Temsirolimus on the developing human fetus are unknown; for this reason men must agree to use contraception from the time of study enrollment continuing for the duration of study participation
Patients must be registered in the MDACC institutional database prior to treatment with study drug
PSA < 40 ng/ml

Exclusion Criteria:

Patients with histologic variants other than adenocarcinoma in the primary tumor
Patients may not be receiving any other investigational agents
Patients may not be receiving concomitant immunotherapy or immunosuppressive therapy
Patients may not have received prior systemic treatment for prostate cancer (other than no more than 3 months of prior treatment with androgen ablation in neoadjuvant and/or adjuvant setting and at least a year must have elapsed since last administration) unless initiation of Androgen Ablation of less than 8 weeks' duration prior to study entry is permitted
Patient with uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring parenteral therapy on day 1 of protocol treatment, symptomatic congestive heart failure resulting in a resting O2 saturation of < 92% on room air, unstable angina pectoris, myocardial infarction within the previous 6 months, or use of ongoing maintenance therapy for life-threatening ventricular arrhythmia, known pulmonary hypertension or pneumonitis
Patients in a severely compromised immunological state, including being positive for the human immunodeficiency virus (HIV) due to possible pharmacokinetic interactions with HAART therapy
Patients diagnosed with acute or chronic hepatitis B or C
Patients using immunosuppressive agents, including intravenous corticosteroids, within 3 weeks of study entry
Patients must not have a history of any other cancer (except nonmelanoma skin cancer), unless in complete remission and off of all therapy for that disease for a minimum of 3 years